Our findings corroborate a recent study that showed that BIS administration suppresses the inflammatory response and extracellular matrix catabolism in advanced glycation end products-treated chondrocytes and attenuates murine osteoarthritis by blocking NF-κB activation [64]. This evidence concerns the gene NFKB1 and osteoarthritis.